{
  "actions": [
    {
      "acted_at": "2001-03-08", 
      "references": [
        {
          "reference": "CR E317", 
          "type": null
        }
      ], 
      "text": "Sponsor introductory remarks on measure.", 
      "type": "action"
    }, 
    {
      "acted_at": "2001-03-08", 
      "committee": "House Committee on Ways and Means", 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Ways and Means.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr946-107", 
  "bill_type": "hr", 
  "committees": [
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "House Ways and Means", 
      "committee_id": "HSWM"
    }
  ], 
  "congress": "107", 
  "cosponsors": [], 
  "enacted_as": null, 
  "history": {
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2001-03-08", 
  "number": "946", 
  "official_title": "To amend the Internal Revenue Code of 1986 to allow drug manufacturers a credit against income tax if they certify that the price of a drug in the United States market is not greater than its price in the Canadian or Mexican market.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "North American Prescription Price Equity Act of 2001", 
  "sponsor": {
    "district": "2", 
    "name": "Duncan, John J., Jr.", 
    "state": "TN", 
    "thomas_id": "00322", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2001-03-08", 
  "subjects": [
    "Business income tax", 
    "Canada", 
    "Commerce", 
    "Drug industry", 
    "Health", 
    "Income tax", 
    "Latin America", 
    "Mexico", 
    "Prescription pricing", 
    "Tax credits", 
    "Tax deductions", 
    "Taxation", 
    "Wholesale trade"
  ], 
  "subjects_top_term": "Taxation", 
  "summary": {
    "as": "Introduced", 
    "date": "2001-03-08", 
    "text": "North American Prescription Price Equity Act of 2001 - Amends the Internal Revenue Code to allow drug manufacturers a limited tax credit if they certify that the wholesale price of a drug in the United States market is not greater than its wholesale price in the Canadian or Mexican market."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "title": "North American Prescription Price Equity Act of 2001", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "title": "To amend the Internal Revenue Code of 1986 to allow drug manufacturers a credit against income tax if they certify that the price of a drug in the United States market is not greater than its price in the Canadian or Mexican market.", 
      "type": "official"
    }
  ], 
  "updated_at": "2013-02-02T20:48:31-05:00"
}